InspireMD Achieves Record Q3 Revenue with CGuard Success
Company Announcements

InspireMD Achieves Record Q3 Revenue with CGuard Success

InspireMD ( (NSPR) ) just unveiled an update.

InspireMD, Inc. has reported record revenue for Q3 2024, driven by its CGuard Prime carotid stent system, which is moving towards potential U.S. approval. Recent developments include submitting a PMA application to the FDA and receiving IDE approval for pivotal trials. The company anticipates a U.S. commercial launch in early 2025, supported by a new Miami headquarters. Despite increased operating expenses, InspireMD’s strategic advancements position it for growth in the carotid artery disease treatment market.

See more insights into NSPR stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskInspireMD Inc. Faces Financial Uncertainty Amidst Ongoing Losses and Cash Flow Challenges
TipRanks Auto-Generated NewsdeskInspireMD Inc. Reports Q3 2024 Financial Results
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App